Upfront Briefing
WCLC closes in Seoul today, and BioNTech got the last word worth having: gotistobart put 18.5 months of median survival against docetaxel’s 10.0 in previously treated squamous lung, on 87 patients and a nominal p-value. Small trial, large number, pivotal stage already enrolling — the kind of result that moves a platform story well before it moves a label. Apollo is in talks to take DePuy Synthes off J&J’s hands for close to $20B, which would be its largest healthcare cheque ever, while the FDA spent four hours on Monday listening to doctors, veterans and pharmacists explain what an approved psychedelic actually looks like inside a clinic. Morgan Stanley’s Global Healthcare Conference runs in New York through Wednesday.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,620.0 |
(0.5%) |
11.1% |
| Nasdaq 100 |
29,127.2 |
(0.8%) |
15.6% |
| Russell 2000 |
2,892.2 |
(0.4%) |
15.3% |
| Healthcare (XLV) |
167.8 |
1.4% |
7.9% |
| Biotech (XBI) |
157.6 |
0.9% |
29.7% |
| Nasdaq Biotech (NBI) |
6,989.8 |
0.9% |
22.5% |
| Clinical Trials (BBC) |
49.9 |
1.1% |
32.7% |
|
- Healthcare took the defensive bid on a risk-off Monday: XLV closed up 1.4% and XBI and NBI both added 0.9% against a 0.5% fall in the S&P 500, with a semiconductor unwind rotating money into the sector and WCLC readouts plus Scholar Rock’s SMA approval giving biotech its own pre-close catalysts.
- The broad tape sagged on an AI-risk scare — Anthropic’s Dario Amodei called over the weekend for slowing frontier development, with Sam Altman and Elon Musk backing him, and a semiconductor gauge fell 5.9% — while Brent settled at $105.68 and the 10-year Treasury yield touched 5% for the first time since 2023 ahead of this week’s Fed decision.
- Market data: U.S. cash close Monday, 14 September 2026.
The Big 3
|
1
|
BioNTech’s gotistobart nearly doubles survival in squamous lung
|
- Gotistobart (BNT316/ONC-392), the CTLA-4 antibody BioNTech runs with OncoC4, produced median overall survival of 18.5 months against 10.0 on docetaxel in stage 1 of the Phase 3 PRESERVE-003 trial at WCLC — 87 patients with metastatic squamous NSCLC who had progressed on prior PD-(L)1 and platinum therapy, HR 0.56, nominal p=0.0295, at a 17 July cutoff and 25.4 months of median follow-up.
- Why it matters: Stage 1 randomised 87 patients and returned a 44% reduction in the risk of death on a nominal p-value — a large effect on a small, non-pivotal sample, which is the whole argument here. The pivotal stage 2 is already enrolling at more than 160 sites, so the read is whether that effect survives a properly powered population, not registrational timing. A confirmed CTLA-4 win in post-IO squamous lung would reprice a class Bristol Myers has largely owned since Yervoy, and hands BioNTech a second oncology asset to bargain with alongside pumitamig. The risk is the familiar one: stage 1 effect sizes this size rarely hold intact.
- Source: GlobeNewswire
- More: BioSpace
|
|
2
|
Apollo circles J&J’s DePuy Synthes at close to $20B
|
- Apollo Global Management is in talks to acquire Johnson & Johnson’s DePuy Synthes orthopedics unit at a valuation close to $20B, with an agreement possible within weeks, rival private equity bidders circling and a public spin still on the table.
- Why it matters: DePuy Synthes turned over $9.3B in 2025, so a $20B headline values it near 2.2x sales — under the roughly $28B enterprise figure Bloomberg Intelligence has floated, and a fair marker for what slow-growth medtech clears at when the buyer is a sponsor rather than a strategic. J&J flagged the separation last October with a tax-free spin as the base case; a sale converts a structural fix into cash it can push back into Innovative Medicine, where it has been buying. The comp that matters for the sector is Blackstone and TPG’s $18B for Hologic. Nothing is signed, a rival bidder can still surface, and the hip-implant litigation tail travels with the asset.
- Source: Fierce Biotech
- More: Bloomberg
|
| 3 | FDA takes four hours of testimony on how a psychedelic ships |
- Doctors, veterans, pharmacists and therapists pressed the FDA at Monday’s four-hour public hearing on provider training, patient screening, clinic capacity and reimbursement for supervised psychedelic sessions that can run six to 12 hours; BioCentury reported the agency could approve on initial efficacy before redosing questions are resolved.
- Why it matters: This was a delivery-economics hearing as much as a regulatory one, and that is the part the equity story keeps skipping. A six-to-12-hour supervised session with credentialed staff in the room puts most of the cost in clinic infrastructure rather than drug margin, and as one speaker put it, approval alone is not access — without reimbursement the sites either serve cash patients or fail. Compass Pathways is furthest along, in a rolling NDA after two pivotal depression wins, with Transcend and Usona also holding national priority vouchers from April. Kevin Sabet supplied the counterweight, arguing the class should clear on trials rather than on the executive order that got it here.
- Source: Fierce Biotech
- More: BioCentury
|
Everything Else that broke
- Cellectis abandoned allogeneic CAR-T for in vivo gene editing and plans to offload its lead programmes. — BioPharma Dive
- Lilly discontinued an early-stage obesity candidate after it failed to clear the company’s internal bar. — Fierce Biotech
- Corbus posted Phase 1 obesity data on a mechanism Novo Nordisk and Sanofi both stumbled on. — Fierce Biotech
- Axoltis missed the mark in a Phase 2 ALS study but said it will still push toward the clinic. — Fierce Biotech
- Definium logged another Phase 3 win for DT120 in anxiety — its third trial success in 12 weeks — and moved closer to an FDA submission. — BioSpace
- GSK will wind down a German vaccine plant, with about 650 jobs affected by weak demand. — Endpoints
- The FDA is reassessing rare-disease trial criteria and endpoint selection for small-population programmes. — Endpoints
- J&J said Rybrevant Faspro plus Lazcluze saw fewer than 1% discontinuations at one year. — PR Newswire
- Lundbeck completed randomisation in its Phase 3 DEEp SEA trial of bexicaserin in Dravet syndrome. — PR Newswire
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Apollo Global Management — in talks to acquire J&J’s DePuy Synthes orthopedics unit at close to $20B; $9.3B of 2025 sales, tax-free spin still the alternative. — Fierce Biotech
VC / Private Financings
- No notable VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- Electra Therapeutics set terms for its Nasdaq IPO (ETRA): 21.67M shares at $14–16 for roughly $325M at the midpoint and up to $347M gross with the greenshoe, valuing it near $978M at the top of the range; proceeds fund ipsoprubart, a pan-SIRP antibody in the registrational Phase 2/3 SURPASS trial in secondary HLH, with Jefferies, TD Cowen, Evercore ISI and Cantor on the books. — Fierce Biotech
- Tyra Biosciences priced a $400M underwritten offering — 9,079,000 shares at $22.03 plus pre-funded warrants over 9,078,529 shares at $22.029 — closing today, four sessions after the SURF302 readout that took the stock down roughly 20%; proceeds go to dabogratinib in low-grade UTUC, intermediate-risk NMIBC and achondroplasia. — PR Newswire
Academic Corner - Azithromycin prophylaxis in cesarean delivery put infection prevention back in focus. — JAMA
- Weight loss in older adults with persistent atrial fibrillation drew follow-up debate after null symptom findings. — JAMA
|
